Clover cancels AIM listing
19 January, 2006 by Ruth BeranSydney-based Clover (ASX:CLV) has applied to the London Stock Exchange to cancel its listing on the Alternative Investment Market (AIM).
New CEO and President for Novogen's US subsidiary
18 January, 2006 by Ruth BeranSydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, has appointed Dr Reinhard Koenig as CEO and president.
Phosphagenics delivers further positive morphine results
18 January, 2006 by Ruth BeranA phase Ib clinical trial of Melbourne-based Phosphagenics' (ASX:POH, AIM:PSG) TPM-01 transdermal delivery system has demonstrated that therapeutic levels of morphine in plasma were achieved and maintained for more than 48 hours using the technology.
Pharmaxis signs first Aridol distributor
18 January, 2006 by Helen SchullerSydney-based drug developer Pharmaxis (ASX:PXS, Nasdaq:PXSL) has signed a European distribution agreement for its first product, Aridol.
Skladnev steps down as Polartechnics CEO
17 January, 2006 by Ruth BeranFollowing a board stoush last year and calls by shareholders at the company's AGM for a change in management, Polartechnics (ASX:PLT) CEO Victor Skladnev was yesterday replaced by Ben Dillon.
Australian researchers awarded $1m Pfizer fellowships
13 January, 2006 by Ruth BeranDr Stephen Nutt, based at the Walter and Eliza Hall Institute, and Dr Anthony Hannan, at the Howard Florey Institute, have each been awarded five-year grants of AUD$1 million under the Pfizer Australia Research Fellowship scheme.
C3 clarifies TGA intention to reject ReCell
12 January, 2006 by Ruth BeranTissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has clarified aspects of its application for approval to market its ReCell product in Australia, following a decision by the Therapeutic Goods Administration (TGA) in December to reject approval for the product.
Novogen's US subsidiary postpones Nasdaq IPO
12 January, 2006 by Ruth BeranSydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, is to postpone its IPO on the Nasdaq national market.
NSW forum to explore research ethics review
11 January, 2006 by Staff WritersThe NSW government's health department is to run a series of forums to explain an ethical review of multi-centre research, including progress towards a model of single ethical and scientific review.
Leroy Hood to consult for LabCorp
11 January, 2006 by Staff WritersSystems biology guru Dr Leroy Hood has entered into a strategic consulting relationship with US molecular testing equipment specialist LabCorp.
Biotech performance was tale of two halves in 2005: Intersuisse
11 January, 2006 by Ruth BeranAustralian biotech stocks underperformed both the All Ordinaries and the Nasdaq Biotech Index in 2005, but the second half of the year was brighter with stocks gaining 23.2 per cent, according to the Intersuisse Biotechnology Index.
Australian experts disappointed by Hwang findings
10 January, 2006 by Staff WritersAustralian stem cell research experts have spoken out, in a series of statements, of their disappointment in the wake of findings by an independent review panel that a team led by South Korean scientist Hwang Woo-suk fabricated research on potentially groundbreaking papers on embryonic stem cells.
A way around a problem
21 December, 2005 by Iain ScottBiotechnology has provided a solution to the problem of how to get science to the market without compromising research, writes editor-in-chief Iain Scott.
Facing up to commercial reality
21 December, 2005 by Ruth BeranThe research community is becoming more sophisticated in the way they approach intellectual property and industry partnerships. Ruth Beran looks at how technology transfer has changed, where it is going and the challenges it faces.
INTERVIEW: Sir Gus's big picture view
15 December, 2005 by Ruth BeranRuth Beran asked Sir Gustav Nossal about Australia's latest institute -- which just happens to bear his name.
